NeuroPace Inc (NASDAQ: NPCE) is 10.01% higher on its value in year-to-date trading and has touched a low of $5.45 and a high of $18.15 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NPCE stock was last observed hovering at around $12.09 in the last trading session, with the day’s gains setting it 0.22%.
Currently trading at $12.31, the stock is -8.37% and 0.55% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.96 million and changing 1.82% at the moment leaves the stock 40.01% off its SMA200. NPCE registered -19.70% loss for a year compared to 6-month gain of 81.83%. The firm has a 50-day simple moving average (SMA 50) of $12.2421 and a 200-day simple moving average (SMA200) of $8.79225.
The stock witnessed a 2.58% loss in the last 1 month and extending the period to 3 months gives it a 72.41%, and is -6.17% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.39% over the week and 8.47% over the month.
NeuroPace Inc (NPCE) has around 171 employees, a market worth around $367.45M and $76.45M in sales. Profit margin for the company is -36.74%. Distance from 52-week low is 125.87% and -32.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.46%).
with sales reaching $21.14M over the same period.The EPS is expected to grow by 22.67% this year, but quarterly earnings will post 21.73% year-over-year. Quarterly sales are estimated to grow 17.39% in year-over-year returns.
NeuroPace Inc (NPCE) Top Institutional Holders
88.0 institutions hold shares in NeuroPace Inc (NPCE), with institutional investors hold 88.49% of the company’s shares. The shares outstanding are 29.78M, and float is at 14.11M with Short Float at 1.55%. Institutions hold 84.87% of the Float.
The top institutional shareholder in the company is ORBIMED ADVISORS LLC with over 3.41 million shares valued at $25.75 million. The investor’s holdings represent 12.0428% of the NPCE Shares outstanding. As of 2024-06-30, the second largest holder is MORGAN STANLEY with 2.47 million shares valued at $18.68 million to account for 8.7365 of the shares outstanding. The other top investors are SOLEUS CAPITAL MANAGEMENT, L.P. which holds 2.43 million shares representing 8.6023% and valued at over $18.39 million, while KENT LAKE CAPITAL LLC holds 4.0454 of the shares totaling 1.14 million with a market value of $8.65 million.
NeuroPace Inc (NPCE) Insider Activity
The most recent transaction is an insider sale by Morrell Martha, the company’s CHIEF MEDICAL OFFICER. SEC filings show that Morrell Martha sold 200 shares of the company’s common stock on Jan 30 ’25 at a price of $15.00 per share for a total of $3000.0. Following the sale, the insider now owns 86762.0 shares.
NeuroPace Inc disclosed in a document filed with the SEC on Jan 29 ’25 that Morrell Martha (CHIEF MEDICAL OFFICER) sold a total of 100 shares of the company’s common stock. The trade occurred on Jan 29 ’25 and was made at $15.00 per share for $1500.0. Following the transaction, the insider now directly holds 86962.0 shares of the NPCE stock.
Still, SEC filings show that on Jan 30 ’25, MARTHA J MORRELL (Officer) Proposed Sale 78,534 shares at an average price of $14.69 for $1.15 million. The insider now directly holds shares of NeuroPace Inc (NPCE).
